Effective vaccine for lassa fever.
Lassa fever has been estimated to cause 5,000 deaths annually in West Africa. Recently, war in the zone where Lassa fever is hyperendemic has severely impeded control and treatment. Vaccination is the most viable control measure. There is no correlation between antibody levels and outcome in human patients, and inactivated vaccines produce high titers of antibodies to all viral proteins but do not prevent virus replication and death in nonhuman primates. Accordingly, we vaccinated 44 macaques with vaccinia virus-expressed Lassa virus structural proteins separately and in combination, with the object of inducing a predominantly TH1-type immune response. Following Lassa virus challenge, all unvaccinated animals died (0% survival). Nine of 10 animals vaccinated with all proteins survived (90% survival). Although no animals that received full-length glycoprotein alone had a high titer of antibody, 17 of 19 survived challenge (88%). In contrast, all animals vaccinated with nucleoprotein developed high titers of antibody but 12 of 15 died (20% survival). All animals vaccinated with single glycoproteins, G1 or G2, died, but all those that received both single glycoproteins (G1 plus G2) at separate sites survived, showing that both glycoproteins are independently important in protection. Neither group had demonstrable antibody levels prior to challenge. We demonstrate that in primates, immune responses to epitopes on both glycoproteins are required to protect against lethal challenge with Lassa virus without having untoward side effects and that this protection is likely to be primarily cell mediated. We show that an effective, safe vaccine against Lassa virus can and should be made and that its evaluation for human populations is a matter of humanitarian priority.
Fisher-Hoch
S P
SP
Special Pathogens Branch, Division of Viral, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Hutwagner
L
L
Brown
B
B
McCormick
J B
JB
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D007835:Lassa Fever / Q000276:immunology / Q000517:prevention & control*; D007836:Lassa virus / Q000276:immunology* / Q000302:isolation & purification / Q000502:physiology; D008252:Macaca fascicularis; D008253:Macaca mulatta; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D019562:Viral Load; D015678:Viral Structural Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014766:Viremia / Q000821:virology
D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D015678:Viral Structural Proteins; D014765:Viral Vaccines